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Abstract 
There are numerous studies that compare different drugs in painful diabetic neuropathy (Bansal, 2009; Goldstein, 2005;  Morello, 
1999; Wernicke, 2007) but our study tries to make a comparison between all four drugs and evaluate the associated depression. 
The study shows the results of drug therapy for painful diabetic non-insulin-dependent neuropathy after 6 months. Four drugs are 
compared for their efficiency and also the global perception of change by the patients. Another aspect is the reduction in 
depression symptoms caused by unsuccessful therapy before using the drugs used in this study. The study shows how the drugs 
are similar in efficiency in pairs of two, one pair of drugs being more efficient than the other.  
© 2014 The Authors. Published by Elsevier Ltd. 
Selection and peer-review under responsibility of the Organizing Committee of WCES 2014. 
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1. Objective 
     To compare the efficacy of pregabaline, gabapentine, sertraline and duloxetine in painful diabetic neuropathy 
(PDN). 
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2.  Research design and methods 
In this observational trial, 28 patients received pregabaline, gabapentine, sertraline and duloxetine orally once 
daily at bedtime for duloxetine and twice in the morning at 8 a clock and at the bedtime, each for 6 months with 
optional dose uptitration (divided in four groups, each group has 7 patients). Pain relief was measured by the 
patient’s global assessment of efficacy, using a visual analogue scale (0–10). Treatment goals include restoring 
function and improving pain control. Patients were randomly selected, the common factor being the presence of 
PDN. Patients of either sex with type 2 diabetes, aged between 25 and 83 years, who were on stable glucose-
lowering medications during the preceding 3 month and who had PDN for at least 1 month were begin to be treated. 
Patients who had a pain score of >5, as assessed by visual analogue scale (VAS), were enrolled in our observation. 
PDN was confirmed by 1) the patient’s medical history, 2) a diabetic neuropathy symptom and increased thresholds 
on the vibration perception test and monofilament test. Patients were excluded if they had any clinically significant 
or unstable medical or psychiatric illnesses. Patients with other causes of neuropathy; renal dysfunction , liver 
disease; psychiatric illness; uncontrolled hypertension; those taking anticonvulsants, antidepressants, local 
anaesthetics, or opioids; those who were pregnant; lactating women; or those being treated with any investigational 
drug within the last 30 days were excluded from this observation. All patients underwent 6 months of treatment with 
one drug and, at the end of 6 months, patients underwent clinical evaluation. One  dose each of sertraline (50 or 100 
mg once daily at bed time), gabapentine 400 mg three times daily with increasing the dose till 2400 mg, 75 
pregabaline twice daily with increasing the dose till 300 mg two times a day  and duloxetine (30 or 60 mg once daily 
at bed time) were used in the study. Treatment was started with the lowest dose of either drug, with fortnightly 
assessments with optional uptitration. The primary end point of the study was the reduction of the average pain 
score from initial results, as assessed by the patient’s global assessment of efficacy by the VAS (0–10 points). 
Secondary end points included the 24-point Hamilton Rating Scale for Depression; and patient self-evaluation of 
overall change on the basis of patient global impression of change scale. Demographic characteristics were noted 
and all the parameters were measured before and after treatment with all four drugs and compared. Patients were not 
allowed any other pain medication. 
 
3.  Results and discussion 
     The study was conducted between January 2012 and June 2012. Population and samples: Total population was 
28 participants randomly selected, divided into 4 groups of 7. Age varies between 25 and 83 years old, mean age 
53.42 (SD 15.75), 12 male patients and 16 female patients, with duration of diabetes between 3 and 17 years, mean 
duration 3.90 (SD 11.03).  
 
4. Gathered data analysis 
Table 1. Values reported on visual analogue scale (VAS) by patients measuring pain.  
 Sertraline Group Gabapentine Group Pregabaline Group Duloxetine Group 
 Before 
Sertrali
ne 
After 
Sertrali
ne 
Before 
Gabapenti
ne 
After 
Gabape
ntine 
Before 
Pregabalin
e 
After 
Pregabalin
e 
Before 
Duloxetin
e 
After 
Duloxetin
e 
Patient  1 5 3 6 5 9 5 8 2 
Patient  2 6 5 7 6 8 2 9 1 
Patient 3 5 3 8 6 7 1 10 3 
Patient 4 7 7 5 5 6 3 8 3 
Patient 5 6 6 9 8 7 5 7 2 
Patient 6 9 8 8 7 9 5 9 1 
Patient 7 8 8 7 6 10 3 10 4 
 
All data collections in above table have been tested for normality of distribution using Shapiro-Wilk normal 
distribution test, and Normal Q-Q Plots. All data collections have been found to have normal distribution.  
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Mean reduction of pain on VAS was calculated for each of the four groups and found a 13.08% improvement in the 
sertraline group, 14% improvement in gabapentine group, 57.25% improvement in pregabaline group and 73.83% 
improvement in duloxetine group. Differences between mean values of pain on VAS for each group were tested 
with t-test for paired samples and were found statistically significant and non-accidental. We based differences 
found on medication treatment for the past six months. Also, using same test there were no statistically significant 
differences found between results of sertraline and gabapentine groups, and not even between pregabaline and 
duloxetine groups, meaning that sertraline showed similar efficiency with gabapentine and pregabaline showed 
similar efficiency with duloxetine. Differences were however statistically significant between sertraline and 
pregabaline or duloxetine and also between gabapentine and pregabaline or duloxetine.  
 
Table 2. Depression scores on Hamilton Scale 
 Sertraline Group Gabapentine Group Pregabaline Group Duloxetine Group 
Hamilton 
Scale 
Score 
initial 
visit 
after 6 
months 
initial visit after 6 
months 
initial 
visit 
after 6 
months 
initial 
visit 
after 6 
months 
Patient  1 11 4 10 6 10 4 11 5 
Patient  2 13 4 9 8 12 4 10 4 
Patient 3 12 4 10 9 13 5 11 6 
Patient 4 12 4 11 10 15 4 12 4 
Patient 5 10 4 8 7 9 4 9 4 
Patient 6 10 4 8 7 8 5 8 4 
Patient 7 10 4 10 5 11 5 10 5 
 
Initial assessment showed normal distribution of scores. The 6 moths visit showed statistically significant reduction 
of depression score for all patients. 
  
Table 3. Overall perception of change 
 Sertraline Group Gabapentine Group Pregabaline Group Duloxetine Group 
Overall 
change 
initial 
visit 
after 6 
months 
initial visit after 6 
months 
initial 
visit 
after 6 
months 
initial 
visit 
after 6 
months 
Patient  1 1 2 1 2 1 4 1 5 
Patient  2 2 3 1 3 2 5 2 5 
Patient 3 1 2 1 2 1 4 1 5 
Patient 4 1 3 1 2 1 5 1 5 
Patient 5 1 2 1 3 1 5 1 5 
Patient 6 1 2 1 2 1 5 1 5 
Patient 7 1 2 1 2 1 5 1 5 
 
Overall perception of change, being a patient self-reported measure, like the VAS, showed similar results as the 
VAS after data analysis.  
 
5.  Conclusions 
     The current study compared the efficacy of duloxetine, pregabaline, gabapentine and sertraline in patients with 
PDN. All drugs demonstrated comparable efficacy as per the established pain-rating scales for PDN. Numerically, 
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more patients have pain relief after duloxetine and pregabaline over sertraline and gabapentin. In the present 
observational study, pregabaline and duloxetine have similar efficacy and more than gabapentine and sertraline. 
More than 73% improvement in pain score was observed with duloxetine, and 57% with pregabaline. Improvement 
in pain was significant and as a result, a significant reduction in depression scores was also observed. The overall 
self-evaluation of patients is consistent with this result. 
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